Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03205696 · ClinicalTrials.gov registry record

Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection

A clinical trial, sponsored by University of California, Los Angeles.

Completed
Registry status
101
Enrollment target

NCT03205696 is a clinical trial that has completed, run by University of California, Los Angeles. The registered enrollment target is 101 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03205696 has completed, sponsored by University of California, Los Angeles.

COMPLETED
Registry status
101 participants
Enrollment target

Study Summary

This is a strategic prospective cohort study which will measure the effects of early intensive antiretroviral therapy (ART) on the establishment and persistence of HIV-1 reservoirs and HIV-1-specific immunity in acutely /recently HIV infected youth aged 12 to 24 years as compared to newly diagnosed youth with established infection \> 6 months. Participants with newly diagnosed acute /recent HIV-1 infection will be offered enrollment into the study with immediate initiation of ART which is the current standard of care.

Interventions

  • DRUG Antiretrovirals

Trial Details

FieldValue
Enrollment Target 101 participants
Start Date 2017-08-01
Est. Completion 2023-11-30

What the Registry Record Tells You About NCT03205696

The ClinicalTrials.gov registry entry for NCT03205696 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Antiretrovirals is the first listed.

NCT03205696 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03205696 about?

NCT03205696 is a clinical study titled "Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection". This is a strategic prospective cohort study which will measure the effects of early intensive antiretroviral therapy (ART) on the establishment and persistence of HIV-1 reservoirs and HIV-1-specific immunity in acutely /recently HIV infected youth aged 12 to 24 years as compared to newly diagnosed ...

What is the current status of trial NCT03205696?

This trial is currently completed. The enrollment target is 101 participants. The study started on 2017-08-01. Estimated completion is 2023-11-30.

What interventions are being tested in trial NCT03205696?

The interventions under investigation include: Antiretrovirals (DRUG).

Who is sponsoring clinical trial NCT03205696?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.